InMode (NASDAQ: INMD) is one of 51 public companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare InMode to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, profitability, earnings and valuation.
Earnings & Valuation
This table compares InMode and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|InMode||$156.36 million||$61.15 million||15.22|
|InMode Competitors||$1.12 billion||$126.03 million||12.05|
InMode’s competitors have higher revenue and earnings than InMode. InMode is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
11.2% of InMode shares are held by institutional investors. Comparatively, 47.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for InMode and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
InMode currently has a consensus target price of $42.25, indicating a potential upside of 73.51%. As a group, “Electromedical equipment” companies have a potential upside of 47.40%. Given InMode’s stronger consensus rating and higher probable upside, analysts clearly believe InMode is more favorable than its competitors.
This table compares InMode and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
InMode beats its competitors on 7 of the 12 factors compared.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.